The role of nutraceuticals in managing metabolic syndrome: a review of clinical studies

Metabolic syndrome (MetS) encompasses a cluster of metabolic disorders including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and elevated fasting glucose. These disorders collectively heighten the risk of cardiovascular disease (CVD), insulin resistance, and type 2 diabetes mellitus (T2DM). With its increasing global prevalence, MetS presents significant public health challenges that necessitate comprehensive management strategies. Traditional treatments primarily involve pharmacological interventions, which are often associated with adverse effects and can lead to patient non-compliance.

Nutraceuticals represent a promising alternative to conventional treatments for MetS. These compounds, derived from whole foods and dietary supplements, are being investigated for their potential benefits in improving insulin sensitivity, and lipid profiles, reducing inflammation, and addressing various components of MetS. This review critically evaluates clinical studies focused on nutraceuticals and their efficacy in enhancing metabolic health. By examining a range of interventions, the review provides evidence supporting the role of nutraceuticals in managing MetS.

The findings of this review are pertinent to patients, researchers, and medical practitioners. For patients, nutraceuticals offer a potentially safer and more tolerable management option that could improve treatment adherence and quality of life. Researchers will benefit from understanding the mechanisms of action of these comp ounds, which can guide future studies aimed at optimizing their clinical use. Medical practitioners can utilize the insights provided to integrate nutraceuticals into their therapeutic strategies, promoting a more holistic approach to managing MetS and mitigating the burden of related chronic diseases. This comprehensive analysis serves as a foundation for advancing patient care and public health in the context of MetS.